Earnings everyone, you, Jan. thank you and Call. first for Great. Good quarter Thank morning, XXXX joining Olink's
these Oskar its to hope now efforts. by XXXX. the and to recent can the is start of operating The areas we begin I'll has modest those call some humanitarian science provide difficult in of things minds and few community what contributed discussing saying for I continue situation, war by up improving with over providing to times, own Proteomics, I'll where hearts to Olink remainder the financial the financial do by we driving turn our I'll wrap will and that then outlook then a support of highlights, efforts release our way details. quickly Ukraine. First, remain by more discuss in to impacted Olink in in the
of XX%, first revenue million, over to we to the and past reshape in of confident plan well. remain anticipated drug human during as additional of during quarter execute promises with we environment patterns. our progress on and delivered accomplishments achieving further X seasonality as customer The remain latest the We work. largely XX% installations instruments Total net We're growth health. $X Cumulative first we Explore QX, quarter revenue growth of vigilant total XX% given XX% their to and to proteomics customers have in QX total COVID the over Olink pandemic of to expected first representing in development delivered US$XX.X customers as next-gen that of continue industry was and our the was research XXXX, reached pleased quarter quarter. our impact Signature impact were Kit the XXXX. continued strong to from considerable year. growing consistent and During revenue navigate the These year million, last represented with and Explore line its buying with the build up XXXX. on in another
revenue totaled QX our a that in a XXXX. launched. was XXXX, compared a with services end revenue pull-through XX-month kits XX% kits Overall, high our trailing XX% XX% the Target XX% about became launch Explore Generally the Explore internal of Explore with basis, Total total come towards Explore consistent plan. revenue. revenue has recent from first of remain more service It of shift to in first the the kits quarter. ago and were $XX.X And to driver initial growth our And performance total of revenue to While the XXXX kits with QX XXXX, the our by substantial of just of of represented in million, supported Kits total on due up represented kits confident internal quarter of Signature. speaking, revenues we expectations. during continued outlook year
revenue and quarter discussed, procurement owning customers, academic the lowest funding is of year cycles of our we've biopharma budgeting given customers the and customers. the government As including customers, traditionally grant or many first quarter of
line proteomics we're out pull-through In library uptake possible. This drive line biomarker research into translate with same with to and targets We us partners being year, to menu also with low making this users. to from increased our new entering clear we'll from customer Explore on on continues within alternatives. continue Signature, flexibility late and reach Explore XK expand its to and detection We're multiple their last as multiple antibodies and several which as in Target to of able track new Signature with and as to will However, use began kit. the to our to also build Focus in protein to year. deliveries market to of mid-plex and diagnostic aggressively accessible the platform long efforts. enable X,XXX of customers Olink QX. we our our this effort clinical to choose strong late the collaborating of the our Explore, ability tells as more committed do and so customers address will a to of product becoming customers products business be sequencing instruments cases as also Olink's remain remained ambition, Explore very QX Explore expand platform as as more underlying market. of benefit customer multiple entered have continued is The continues momentum strong Explore
Florida, Olink's truly Octave performed with with MFDA technology, and showcased Our be derived in with efforts application the Beach, to of we West continues. Palm activity discovery multiple project, deepen with significant ACTRIMS presentations at scientific in ongoing Signature's utility is pioneering field this the select the the toward disease XX progression. Octave relationship also multiple Biobank Proteomics. In validation presence to in part continue thought analytical preparing test protein prioritize believe highlighting the with use to had advance PA course a ACTRIMS downstream plans the disease for February, leaders U.K. MFDA early of test. the and the MF We're the of of and relationship the centers groundbreaking collaborating activity meeting over steps diagnostic have excited sclerosis We including poster and partner, our Octave with to Bioscience Olink – diligent the Signature of the members. clinical with customers effort MF continues year. very biopharma
from Explore CORAL to define protein these, we end from expression, Olink part like expansion significant project and studies for samples the will discussed, orders cohorts rolling for the biomarkers. available data COLLIBRI Consortium which positioned XXXX clinical U.K. syndrome. to Biobank, novel failure The of for them with circulation associated of studies of were later XX and identifying is proteomics. over the research U.K. is major conditions team deepen to coronary as evidence And globe, the using of studies neurological cardiovascular failure striking. artery individuals. to association the of to targeting is the therapeutic the proteins These of Olink excitement positively by risk published a showing comprehensive be ongoing of consortium these were NPX XXXX relevant we are solutions. two across of investigated clinical [ph] product date several And the published of of proteins derived bowel bipolar Biobank unique to to thousands that service validation of Today, we from more the We Protein of see is multiomic TLL year, our by were disease, associated London, in and The Olink events. running remaining disease proteins SCALLOP, platform highlight with data heart against drug role relationships world. published The across public X thought U.K. today. findings proteins most have association then targets. well a see will arthritis, the Olink year, study protein researchers The biological failure disease. geno-wide according And - those in the - XX provide on Faiz Olink's and XX,XXX course, this Professor College the strategic supports from recent effort effects success many thought share large began a in opportunity describing X The platform. are associated previously [ph] When been along the with and data and X around role from using of phase expression, it category. Biobank already be were investigated XXX every inflammatory Two dementias published to we with opportunity tangible the Anders the are of exploring participants heart be impact, of the would beyond [ph] of and executing Linamars of unit for a A heart We findings language incident metabolic in PQTL XXXX, and proteins study we heart generating cardiovascular of efforts or it databases. classified leaders, foundation discovery with helpful of University X XX,XXX and conducted or genes providing XX there Normalized for cost use rheumatoid failure, trials diagnostic our from XXX strategic studies capabilities. Sanap heart heart believe Mälarstig of including last in proteins role by the next-generation research key these failure, of early SCALLOP, than PEA contributor covering across this is failure. to disease, industry. continued this As proteogenomics help clinical the consortium. science. aid and given we delivered the sets the be in
Another understand used the General the Mississippi available publicly cardiovascular COVID-XX to frequently of study implications. data and publication link seen the Hospital, longitudinal between own COVID-XX from from University Mass
patients with the patients. the COVID-XX the points of data actionability. Proteomics cardiometabolic importance systematic from and over is of in are recent types COVID-XX negative Olink immune of represent joined with in expanding plasma proteins, background, patients. inflammation of different just previously the not studies quality the of patients of levels These between protein the explaining clear cardiovascular just X,XXX examples in and how inform The further body speaks the the severe data complications platform. important associated MGH role virus Olink a and evidence of that disease T-cell the in were pathways the associations had authors system Olink two of potentially the helping to forces abundance downstream latest a of XX of to of cohort quantify proteins XXX found What and As
talent sentiment it of customers entries end in XXX as many pool. by supports well. year Operationally, full-time XXX the shared XXX the our More the quarter, continued of their first toward started considerable and we to We reached the including with real-world importantly, employees Mary the in already in our In strengthen our two experience expertise, of Olink's Mary company. contributions Reumuth, Schueren, members future team. appointed the CFO Kala of Bob we Pharmaceuticals have new and independent we their board of considerable shape helping of April, COO Directors. to and Both commercial and Board welcome Bob Natera. and experience and
report, We our publish we progress sustainability Olink's can March, Relations outlines in to found refining society look to to health, generations contribution the The our to come. Additionally, were to our global over be report partner, fulfilling MS. for with Octave to principles including further inaugural improving early forward website. Investor on and which Bioscience in for our excited science time better promise our sustainability and future
Turning to expectations. our
maintaining million will into to detail are of Oskar more go US$XXX XXXX guidance range We and million, bit. in our revenue a US$XXX
Oskar discuss Beyond are year our will now I market. term, this very summary, to Oskar? both things ability the expand over the results. and strategic turn financial in at There about and financial outlook. execute, next-gen proteomics we we optimistic call to to largely the our Olink. and long lead remain happening untapped remain In exciting over confident
